With the massive guide-down miss by Hexo and The Green Organic Dutchman’s backing away from 2020 guidance, we are witnessing a resetting of especially aggressive revenue-growth expectations in the cannabis industry.
Recently, several companies have announced challenges with financing their expansion plans. The trend doesn’t bode well for many operators in cannabis.
This comp table provides a benchmark for private investors to evaluate existing and future investments as well as a menu for public investors to peruse.
German medical cannabis company Demecan has secured 7 million euros ($7.6 million) in financing to expand production in Europe’s largest medical market.
This comp table provides a benchmark for private investors to evaluate existing and future investments as well as a menu for public investors to peruse.
This comp table provides a benchmark for private investors to evaluate existing and future investments as well as a menu for public investors to peruse.
The cannabis industry changes so rapidly that investors must always be aware of new information. This catalyst calendar provides you with key events that may impact your investments and investment decisions over the next month.
This comp table provides a benchmark for private investors to evaluate existing and future investments as well as a menu for public investors to peruse.
